ASLAN Pharmaceuticals Limited (ASLN) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Singapore, 新加坡. 现任CEO为 Carl Alan Jason Morton Firth EMBA,.
ASLN 拥有 IPO日期为 2018-05-04, 35 名全职员工, 在 NASDAQ Global Market, 市值为 $777.12M.
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
